BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» After a Bumpy Road, Can RNA Therapeutics Prosper in 2013?
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
After a Bumpy Road, Can RNA Therapeutics Prosper in 2013?
Jan. 7, 2013
By
Brian Orelli
No Comments
"I absolutely believe there will be an RNAi drug [on the market] within 10 years," Nassim Usman, COO and senior VP, Sirna Therapeutics Inc., said in a 2005 interview for BioWorld's RNAi Report.
BioWorld